USA flag logo/image

An Official Website of the United States Government

Novel Platform Technology for Developing Therapeutic Human mAbs

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
85419
Program Year/Program:
2007 / SBIR
Agency Tracking Number:
CA126070
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
NEOCLONE BIOTECHNOLOGY INTERNATIONAL
1202 Ann St MADISON, WI 53713-2410
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2007
Title: Novel Platform Technology for Developing Therapeutic Human mAbs
Agency: HHS
Contract: 1R43CA126070-01A1
Award Amount: $140,000.00
 

Abstract:

DESCRIPTION (provided by applicant): Despite significant advances in treatment and early detection, cancer remains a significant disease threat to society. Therapeutic monoclonal antibodies are effective new treatments that have recently been developed as targeted therapies against many types of cancer. Over 17 monoclonal antibodies have been approved in the US for treating a variety of diseases. The advantages are high specificity, predictable side effects, and more rapid and less expensive advancement thr ough clinical trials. Significant hurdles remain, however, including the low efficiency of antibody development, instability of hybridoma cell lines, adverse patient immune responses to foreign protein or carbohydrate sequences, and commercially, royalty s tacking issues from the need to access the multiple technologies required to develop an efficacious antibody therapeutic. There is currently no technology platform that allows one to develop human monoclonal antibody producing cell lines by direct transfor mation of human immune cells. Such antibodies can be tested for specific therapeutic characteristics and the cell lines directly scaled for larger antibody manufacturing without the use of additional platform technologies. The approach described herein is one that allows for more rapid discovery of high value therapeutic products, that will both personalize and revolutionize the therapeutic human monoclonal antibody as the new era of genomics and proteomics continues to provide enormous opportunity for the discovery of druggable targets. The objective of this Phase I proposal is utilize the ABL-MYC retroviral transformation technology for the development of fully human monoclonal antibodies. NeoClone has utilized this approach commercially since 1999 to deve lop murine antibodies for research and diagnostic use. If successful in this proposal, the advantages of our murine antibody technology would hold true: rapid, efficient, cost effective development of high affinity monoclonal antibodies. Additional advanta ges for therapeutics would be fully human antibody sequence, stable cell lines, accurate post-translational modifications and no need for further maturation to improve affinity. Additionally, this technology would have the potential to use the patient's ow n cells for antibody development. A more rapid and efficacious therapeutic antibody technology would be a welcome addition to the arsenal of approaches to combat cancer and other deadly diseases. Therapeutic monoclonal antibodies are emerging as one of the most effective targeted drug approaches for cancer. NeoClone is proposing to adapt it's successful monoclonal antibody technology to enable rapid development of fully human therapeutic monoclonal antibodies. The potential advantages of this approach are m ore rapid and efficient drug development with less potential for deleterious side effects.

Principal Investigator:

Rachel H. Kravitz
6082608190
RKRAVITZ@NEOCLONE.COM

Business Contact:


deven@neoclone.com
Small Business Information at Submission:

NEOCLONE BIOTECHNOLOGY INTERNATIONAL
NEOCLONE BIOTECHNOLOGY INTERNATIONAL,LLC 1202 ANN ST MADISON, WI 53713

EIN/Tax ID: 139198167
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No